Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…
PTC THERAPEUTICS, INC.
Last earnings -3.1% on 2026-05-07
Revenue grew 114.5% YoY.
Rules-based read computed from SEC figures — no Anthropic key set. Add ANTHROPIC_API_KEY to .env.local for a full Claude analysis.
PTC THERAPEUTICS, INC. shows $1.73B in FY2025 revenue (+114.5% YoY), a 39.4% net margin, and -332.5% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
Sources: SEC EDGAR (CIK 0001070081, latest 10-Q filed 2026-05-07) · EODHD · rules-based read · as of 6/18/2026, 10:36:50 AM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $539M | $699M | $938M | $807M | $1.73B |
| Gross profit | — | — | — | — | — |
| Operating income | -$374M | -$447M | -$440M | -$303M | $867M |
| Net income | -$524M | -$559M | -$627M | -$363M | $683M |
| Diluted EPS | -$7.43 | -$7.79 | -$8.37 | -$4.73 | $7.78 |
| Net margin | -97.3% | -80.0% | -66.8% | -45.0% | 39.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
501 tracked peers · median
Last 90 days: 0 open-market buys · 19 sales
| 2026-06-10 | Pauwels Eric CHIEF BUSINESS OFFICER | Sell | 3.71K @ $75.00 | $278K |
| 2026-06-10 | Pauwels Eric CHIEF BUSINESS OFFICER | Exercise | 17.6K @ $18.01 | $316K |
| 2026-06-10 | Pauwels Eric CHIEF BUSINESS OFFICER | Sell | 17.6K @ $75.00 | $1.32M |
| 2026-05-15 | Boulding Mark Elliott EXEC. VP AND CLO | Exercise | 2.81K @ $25.69 | $72.2K |
| 2026-05-15 | Boulding Mark Elliott EXEC. VP AND CLO | Sell | 2.36K @ $72.08 | $170K |
| 2026-05-15 | Boulding Mark Elliott EXEC. VP AND CLO | Sell | 456.00 @ $72.67 | $33.1K |
| 2026-05-14 | Klein Matthew B. CHIEF EXECUTIVE OFFICER | Sell | 679.00 @ $73.06 | $49.6K |
| 2026-05-14 | Klein Matthew B. CHIEF EXECUTIVE OFFICER | Sell | 7.22K @ $73.08 | $528K |
| 2026-05-14 | Klein Matthew B. CHIEF EXECUTIVE OFFICER | Sell | 2.10K @ $73.08 | $153K |
| 2026-05-14 | Klein Matthew B. CHIEF EXECUTIVE OFFICER | Sell | 2.57K @ $72.46 | $186K |
| 2026-05-13 | Klein Matthew B. CHIEF EXECUTIVE OFFICER | Award | 12.5K | |
| 2026-05-08 | Boulding Mark Elliott EXEC. VP AND CLO | Exercise | 2.74K @ $46.54 | $128K |